Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 72, Issue 5, 2011, Pages 716-721

  Berlin, Heather A ^a   Koran, Lorrin M ^b   Jenike, Michael A ^c   Shapira, Nathan A ^d   Chaplin, William ^e   Pallanti, Stefano ^a   Hollander, Eric ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ST JOHN'S UNIVERSITY   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; COMPULSION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; INSOMNIA; MALE; MEMORY DISORDER; MULTICENTER STUDY; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; PARALLEL DESIGN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; THERAPY RESISTANCE; TOOTH PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT REDUCTION; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FRUCTOSE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959251365     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05266gre     Document Type: Article

References (56)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry. 1999;60(suppl 18):27-32. PubMed
3. DuPont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Med Interface. 1995;8(4):102-109. PubMed
4. Steketee G. Disability and family burden in obsessive-compulsive disorder. Can J Psychiatry. 1997;42(9):919-928. PubMed
5. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):509-517. doi:10.1016/S0193-953X(05)7017-5 PubMed (Pubitemid 30666503)
6. Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360(9330): 397-405. doi:10.1016/S0140-6736(02)09620-4 PubMed
7. Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44(11):946-951. PubMed
8. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder; behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992;49(1):21-28. PubMed
9. Stein DJ, Van Heerden B, Wessels CJ, et al. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23(6):1079-1099. doi:10.1016/S0278-5846(9)051-2 PubMed (Pubitemid 29468915)
10. Adams KH, Hansen ES, Pinborg LH, et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol. 2005;8(3):391-401. doi:10.1017/S1461457050505 PubMed (Pubitemid 41002493)
11. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3(1):69-81. doi:10.1016/j.nurx.205.12.06 PubMed (Pubitemid 43276634)
12. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 2000;877(1): 23-30. doi:10.1016/S06-893(0)02646-9 PubMed
13. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58(5):424-428. doi:10.1016/j.biopsych.205.04.043 PubMed (Pubitemid 41219711)
14. Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction-newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov. 2007; 2(1):47-55. (Pubitemid 46729090)
15. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety. 2006;23(1):1-5. doi:10.102/da.2018 PubMed
16. Rubio G, Jiménez-Arriero MA, Martínez-Gras I, et al. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006;26(3):341-344. PubMed doi:10.1097/01.jcp.020524.4905.9f
17. Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatmentresistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2006;21(3):189-191. PubMed doi:10.1097/01.yic.019453.5479.c
18. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl). 2003;167(2):219-220. PubMed
19. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006;184(2):254-256. doi:10.107/s0213-05-0246-6 PubMed (Pubitemid 43084809)
20. Koran LM, Hanna GL, Hollander E, et al; American Psychiatric Association. Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Am J Psychiatry. 2007;164(suppl):5-53. PubMed
21. Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry. 1987;22(9):1169-1171. doi:10.1016/06-323(87)9061-8 PubMed (Pubitemid 17138313)
22. Corá-Locatelli G, Greenberg BD, Martin J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59(9):480-481. PubMed
23. Sporn J, Smith M, Jersino JM, et al. A double-blind, placebo-controlled trial of gabapentin (GBP) augmentation of fluoxetine for treatment of obsessive-compulsive disorder (OCD). Poster presented at: New Clinical Drug Evaluation Unit Program; May 28-31; 2001; Phoenix, AZ.
24. Hollander E, Pallanti S. Current and experimental therapeutics of OCD. In: Davis KL, Charney D, Coyle JT, et al, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott William & Wilkins; 2003:1647-1664.
25. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68(1):1-23. doi:10.1016/S0165-0327(0)029-8 PubMed
26. Baxter LR. Functional imaging of brain systems mediating obsessive-compulsive disorder. In: Charney DS, Nestler EJ, Bunney BS, eds. Neurobiology of Mental Illness. New York: Oxford University Press; 2001:534-547.
27. Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2001;4(2):179-190. doi:10.1017/S14614570102401 PubMed (Pubitemid 32587386)
28. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry. 2002;7(6):617-625, 524. doi:10.1038/sj.mp.4014 PubMed
29. Whiteside SP, Port JD, Deacon BJ, et al. A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res. 2006;146(2):137-147. doi:10.1016/j.pscychresns.205.12.06 PubMed
30. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096-1103. doi:10.1097/04583-2090-08 PubMed
31. Moore GJ, MacMaster FP, Stewart C, et al. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(6):663-667. PubMed
32. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735-1740. doi:10.1038/sj.np.13073 PubMed (Pubitemid 43086030)
33. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007;448(7156):894-900. doi:10.1038/nature06104 PubMed (Pubitemid 47312780)
34. Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004;174(4):530-538. doi:10.107/s0213-04-1847-1 PubMed (Pubitemid 39119342)
35. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(7):769-776. doi:10.101/archpsyc.63.7.769 PubMed
36. Delorme R, Krebs MO, Chabane N, et al. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport. 2004;15(4):699-702. doi:10.1097/01756-2040320- 025 PubMed (Pubitemid 38457164)
37. Grados M, Wilcox HC. Genetics of obsessive-compulsive disorder: a research update. Expert Rev Neurother. 2007;7(8):967-980. doi:10.1586/14737175. 7.8.967 PubMed (Pubitemid 47287485)
38. Stewart SE, Fagerness JA, Platko J, et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):1027-1033. doi:10.102/ajmg.b.3053 PubMed (Pubitemid 350207777)
39. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(7):778-785. doi:10.101/archpsyc.63.7.78 PubMed
40. Veenstra-VanderWeele J, Kim SJ, Gonen D, et al. Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder. Mol Psychiatry. 2001;6(2):160-167. doi:10.1038/sj.mp.40806 PubMed (Pubitemid 32187865)
41. Taverna S, Sancini G, Mantegazza M, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999;288(3):960-968. PubMed
42. White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(suppl 1):S17-S20. doi:10.1/j.1528-157.20.tb06042.x PubMed (Pubitemid 30202335)
43. Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage- activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(suppl 1):S52-S60. doi:10.1/j.1528-157.20.tb02173.x PubMed (Pubitemid 30202343)
44. Pallanti S, Hollander E, Bienstock C, et al; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181-191. doi:10.1017/S1461457020290 PubMed (Pubitemid 34669829)
45. Vinkers DJ, van der Wee NJ. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder [in Dutch]. Tijdschr Psychiatr. 2008;50(11):747-750. PubMed
46. Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry. 2005;66(11):1492-1493. doi:10.408/JCP.v6n121d PubMed (Pubitemid 41779556)
47. Thuile J, Even C, Guelfi JD. Topiramate may induce obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2006;60(3):394. doi:10.1/j.140-1819.206. 01520.x PubMed (Pubitemid 43736408)
48. Ozkara C, Ozmen M, Erdogan A, et al. Topiramate related obsessive-compulsive disorder. Eur Psychiatry. 2005;20(1):78-79. doi:10.1016/j.eurpsy.204.09.015 PubMed (Pubitemid 40092398)
49. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCIDI/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
50. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. PubMed
51. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry. 1989; 46(11):1012-1016. PubMed
52. Montgomery SA, Asberg MC. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
53. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
54. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1983.
55. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry. 2007;68(suppl 12):18-26. PubMed
56. Ciranna L. Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol. 2006;4(2):101-114. doi:10.2174/15701590676359540 PubMed